ResearcherFirst Affiliated Hospital Zhejiang UniversityNo recent work listed

Kwabena Gyabaah Owusu-Ansah

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6566-3222; OpenAlex author ID A5017611619. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. Co-author DOI 10.1016/j.heliyon.2022.e12064 ↗
COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3892/ijo.2019.4825 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Donghai Jiang · 2 shared papers, 2019–2022 · strength 0.28
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
- Paper COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer. DOI 10.3892/ijo.2019.4825 ↗
Shusen Zheng · 2 shared papers, 2019–2022 · strength 0.28
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
- Paper COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer. DOI 10.3892/ijo.2019.4825 ↗
Wan-Wen Weng · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
Jiawei Hong · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.